Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin.
Haematologica
; 91(6 Suppl): ECR26, 2006 Jun.
Article
em En
| MEDLINE
| ID: mdl-16785129
ABSTRACT
Peginterferon (Peg-IFN) alfa in combination with ribavirin represents the gold standard treatment for chronic hepatitis C, but is associated with various side effects, especially hematological abnormalities. We report here a case of severe autoimmune hemolytic anemia (AIHA) complicated by symptomatic myocardial ischemia in a patient with chronic hepatitis C during combination therapy. The worsening hemolysis after ribavirin withdrawal and exclusion of other causes implicated Peg-IFN alfa as the cause of AIHA. Our study demonstrates that in patients without preexisting immunological abnormalities Peg-IFN can de novo induce autoimmune complications that, albeit rarely, may be life-threatening.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Polietilenoglicóis
/
Ribavirina
/
Interferon-alfa
/
Hepatite C Crônica
/
Anemia Hemolítica Autoimune
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Haematologica
Ano de publicação:
2006
Tipo de documento:
Article
País de afiliação:
Itália